Connors Investor Services’s Ligand Pharmaceuticals LGND Stock Holding History

Connors Investor Services’s Portfolio LGND Stock Details LGND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.44M	Buy	+10,880	New	+$2.56M	0.3%	62

Other funds holding LGND

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Jupiter Topco New York $245B AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

CAM

Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Connors Investor Services's LGND Position: Q2 2026 in Review

Connors Investor Services opened a new position in Ligand Pharmaceuticals (LGND) in Q2 2026: 10,880 shares worth $3.44M. The stake represents 0.3% of the portfolio and ranks #62 among its holdings.

414 funds tracked by Wall St. Rank hold LGND as of Q2 2026.

Connors Investor Services held 10,880 shares of Ligand Pharmaceuticals worth $3.44M as of Q2 2026.
Ligand Pharmaceuticals was a new Connors Investor Services position in Q2 2026.
Ligand Pharmaceuticals made up 0.3% of Connors Investor Services's portfolio in Q2 2026, its #62 holding.
414 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2026.

Based on Connors Investor Services's 13F filing for Q2 2026, filed 14 Aug 2026.